<div id="readability-page-1"><p>Helius Medical Technologies Inc ((HSDT)) has held its Q1 earnings call. Read on for the main highlights of the call.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Helius Medical Technologies’ latest earnings call painted a complex picture for investors. Management highlighted explosive revenue growth from its Solana-focused staking strategy and early traction in new infrastructure and advisory lines, yet the quarter was overshadowed by heavy mark-to-market losses, lean liquidity, rising costs and growing dilution that together underscore elevated risk.</p> <h2>Explosive Revenue Growth From Staking</h2> <p>Helius reported Q1 2026 revenue of $3.6 million, a dramatic jump from just $49,000 a year earlier, an increase of more than 7,200%. The surge was driven primarily by $3.4 million in staking revenue, with another $0.2 million coming from other sources, underscoring how central the Solana treasury strategy has become to the business model.</p> <h2>Return To Positive Gross Profit</h2> <p>Gross profit swung sharply into positive territory, reaching $3.4 million in Q1 2026 compared with a gross loss of $72,000 in the prior-year quarter. Management linked the turnaround directly to the high-margin nature of staking income, suggesting that, at least at the gross level, the pivot to digital asset yield is materially improving economics.</p> <h2>Staking Yield Outperformance Versus The Network</h2> <p>The company posted an average net staking yield of 6.9% in Q1 2026, beating the roughly 6.0% system-wide average by about 90 basis points. Helius emphasized that staking rewards, totaling 32,500 SOL in the quarter versus 34,000 SOL in Q4 2025, are automatically restaked to compound returns, aiming to enhance long-term value from the Solana holdings.</p> <h2>Significant Solana Treasury With Limited Cash</h2> <p>As of March 31, 2026, Helius held approximately $193.8 million of Solana across liquid holdings, stake positions and receivables, reinforcing its identity as a Solana-heavy treasury vehicle. Yet cash and cash equivalents stood at only $4.4 million, a contrast that highlights both the scale of its digital asset exposure and the constraints around day-to-day liquidity.</p> <h2>Accretive Capital Raise And Share Buybacks</h2> <p>In capital markets activity, the company completed an $8 million strategic equity raise at $2.60 per share, or roughly 1.1 times management’s stated mNAV, which it described as immediately accretive to SOL-per-share. Helius also executed about $3.5 million of share repurchases in Q1 and roughly $5.0 million year-to-date, funding buybacks through strategic sales of SOL at levels it deemed accretive.</p> <h2>New Infrastructure And MEV Partnerships</h2> <p>Helius announced its Pacific Backbone initiative, an institutional-grade validation infrastructure with an initial three nodes targeted to be operational in late June. The company also unveiled a strategic partnership with Jito designed to enhance MEV and yield optimization for its validator operations, aiming to further lift net staking returns and differentiate its platform.</p> <h2>Advisory And Platform Momentum In APAC</h2> <p>Management described its advisory business as already revenue-generating, with contracts in process and a lean initial team structure. The strategy is to build a recurring revenue flywheel that connects advisory, infrastructure and platform offerings, with a particular focus on attracting institutional demand for Solana and digital asset services across the Asia-Pacific region.</p> <h2>Cost Cuts And Exit From Legacy Medical Assets</h2> <p>To streamline operations, Helius completed the divestiture of its cash-burning PoNS and medical device businesses in the second quarter, alongside other cost rationalization moves. These steps are expected to deliver a positive recurring financial impact starting in Q2, allowing the company to redeploy resources toward its digital treasury and infrastructure initiatives.</p> <h2>Heavy Unrealized Losses From SOL Price Decline</h2> <p>The quarter’s headline risk came from an $89.2 million unrealized loss on digital assets and related receivables, driven by an approximate 33% decline in SOL price from year-end 2025 through March 31. These mark-to-market hits underscore the company’s sensitivity to Solana price swings and the volatility embedded in its treasury strategy.</p> <h2>Net Loss Swells On Noncash Charges</h2> <p>Helius reported a net loss of $99.8 million for Q1 2026, or $1.30 per share, versus a $3.8 million loss in the prior-year quarter. Total operating expenses surged to $103.1 million from $3.9 million, with management noting that a large portion reflected noncash unrealized losses, though the headline figures still highlight the scale of recent financial headwinds.</p> <h2>Realized Losses From SOL Sales</h2> <p>Beyond the mark-to-market impact, the company recognized $7.0 million of realized losses on capital and digital assets tied to strategic SOL sales used to fund capital allocation initiatives. While management framed these trades as accretive in terms of SOL-per-share and repurchase economics, they confirm that some value was crystallized at lower prices during the quarter.</p> <h2>Liquidity Tightness And Funding Risk</h2> <p>Cash and cash equivalents of $4.4 million at quarter-end raise questions about liquidity in light of ongoing investments and operating needs. Although the April $8 million raise bolsters the buffer, investors must weigh the company’s dependence on volatile digital asset holdings and capital markets access to support the current growth strategy.</p> <h2>Ongoing Dilution For Shareholders</h2> <p>Helius reported a diluted share count of 82.5 million as of March 31, 2026, rising to 86.0 million by May 12, an increase of about 4.2%. The uptick reflects recent equity issuance, adding a layer of dilution on top of the firm’s buyback program and highlighting the trade-off between balance sheet reinforcement and per-share ownership.</p> <h2>Market Volatility And Strategy Execution Risk</h2> <p>Management acknowledged that SOL’s roughly 33% decline during the quarter created significant mark-to-market losses and adds execution risk to the treasury strategy. The team also could not provide firm guidance on third-party SOL delegation volumes or board-approved SG&amp;A run-rate targets, leaving investors with limited near-term visibility into scale and cost trajectories.</p> <h2>Underlying Expense Growth Beyond Noncash Items</h2> <p>Even excluding noncash elements, operating costs are rising, with general and administrative expenses increasing to $5.2 million in Q1 2026 from $3.9 million a year earlier. Management attributed the growth to expanded operations tied to the digital treasury strategy and signaled that discretionary spending is likely to continue as the business scales out its platform.</p> <h2>Forward-Looking Outlook And Strategic Priorities</h2> <p>Looking ahead, Helius expects the operational benefits of its Solana treasury strategy to become more evident within the current fiscal year as the initial Pacific Backbone nodes go live and third-party SOL delegation ramps from existing verbal commitments. The company plans to continue automatically restaking rewards, pursue opportunistic capital allocation including buybacks and SOL purchases, and leverage its Jito partnership and recent divestitures to improve yield capture and financial performance, though management’s lack of firm quantitative guidance underscores ongoing uncertainty.</p> <p>Helius’ earnings call framed a company in transition, with rapid revenue growth, improving gross profitability and new infrastructure partnerships set against severe unrealized losses, limited cash and rising dilution. For investors, the story hinges on whether management can successfully execute its Solana-centric strategy, convert advisory and infrastructure efforts into recurring revenue and manage volatility risk without overburdening the balance sheet.</p></div>

HSDT

SOLZ

BSOL

GSOL

<p>Helius Medical Technologies reported explosive Q1 2026 revenue growth of 7,200% to $3.6 million, driven by staking income. However, the company faced significant challenges, including an $89.2 million unrealized loss on digital assets and a net loss of $99.8 million. Despite a strong Solana treasury of $193.8 million, liquidity concerns arose with only $4.4 million in cash. Helius is focusing on cost cuts and new partnerships to enhance its digital asset strategy while navigating market volatility.</p>

Helius Medical Technologies Earnings Call Highlights Volatility